Sort
326,823 grants matching “clinical trial”
University of New Mexico Cancer Center Support Grant
$2,246,011Cheryl L Willman · University Of New Mexico Health Scis Ctr · P30 · FY2016 · CA
University of New Mexico Cancer Center Support Grant
$2,246,011Cheryl L Willman · University Of New Mexico Health Scis Ctr · P30 · FY2017 · CA
University of New Mexico Cancer Center Support Grant
$2,246,011Alan E Tomkinson · University Of New Mexico Health Scis Ctr · P30 · FY2019 · CA
Dana-Farber/Harvard SPORE in Breast Cancer
$2,245,949James Dirk Iglehart · Dana-Farber Cancer Inst · P50 · FY2006 · CA
Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies
$2,245,877Franziska Michor · Dana-Farber Cancer Inst · U54 · FY2017 · CA
Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas
$2,245,802Michael J Brownstein · Myosin Therapeutics Inc. · R44 · FY2025 · CA
Advancing brain health research through male germline editing in marmosets
$2,245,765Brian Peter Hermann · University Of Texas San Antonio · U01 · FY2025 · DA
Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.
$2,245,745Christopher Hourigan · National Heart, Lung, And Blood Institute · ZIA · FY2016 · HL
ECOG-ACRIN Biorepositories to Support NCTN
$2,245,660Ignacio I. Wistuba · Ecog-Acrin Medical Research Foundation · U24 · FY2016 · CA
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
$2,245,572Alan David D'andrea · Dana-Farber Cancer Inst · P50 · FY2023 · CA
Colon Cancer Family Registry Cohort
$2,245,339Robert William Haile · Stanford University · UM1 · FY2016 · CA
In vivo proton MRS studies:cerebral injury in HIV infection
$2,245,305Bradford A Navia · Tufts University Boston · R01 · FY2008 · NS
Phenotypic Analysis of Islet Antigen-specific Effector T Cells in Pre-diabetic Subjects
$2,244,957William W. Kwok · Benaroya Research Inst At Virginia Mason · DP3 · FY2015 · DK
COG Biospecimen Bank
$2,244,903Nilsa Del Carmen Ramirez · Research Inst Nationwide Children'S Hosp · U24 · FY2018 · CA
COG Biospecimen Bank
$2,244,903Nilsa Del Carmen Ramirez · Research Inst Nationwide Children'S Hosp · U24 · FY2016 · CA
COG Biospecimen Bank
$2,244,903Nilsa Del Carmen Ramirez · Research Inst Nationwide Children'S Hosp · U24 · FY2017 · CA
SPORE in Prostate Cancer
$2,244,780Donald J. Tindall · Mayo Clinic Rochester · P50 · FY2006 · CA
Translational Research to Prevent and Control Global Infectious Diseases (Translational Global Infectious Diseases Research Center, TGIR).
$2,244,419Beth Diane Kirkpatrick · University Of Vermont & St Agric College · P20 · FY2019 · GM
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
$2,244,254Julianne L Imperato-McGinley · Weill Medical Coll Of Cornell Univ · UL1 · FY2010 · RR
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
$2,244,253Julianne L Imperato-McGinley · Weill Medical Coll Of Cornell Univ · UL1 · FY2010 · RR
DCTD In Vivo Preclinical Testing
$2,244,224David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2013 · CA
Coronary Artery Calcium in the PRagmatic EValuation of evENTs And Benefits of Lipid lowering in the Elderly: CAC PREVENTABLE Ancillary Study
$2,244,161Melissa Daubert · Duke University · R01 · FY2023 · HL
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and Resilience
$2,243,953Sudha Seshadri · University Of Texas Hlth Science Center · R01 · FY2020 · AG
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
$2,243,861Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2024 · AG
Manufacture of a Vaccine Targeting Frame-Shift Mutations Characteristic of Tumors with Microsatellite Instability
$2,243,667Beth Tebeau · Advanced Bioscience Laboratories, Inc. · N01 · FY2020 · CA